Nat Med Clinical Discovery! Il-8 levels in blood and tumors are associated with the clinical benefits of PD-L1 inhibitors!

May 14, 2020 News /BiovalleyBIOON / - although plasma interleukin -8 (pIL-8) increased immune checkpoint defective block outcomes, but this has not been fully evaluated in a large randomized studyRecently researchers from Genentech, published in the journal NatureMedicine research paper entitled "Highsystemicandtumor-associatedIL-8correlateswithreducedclinicalbenefitofPD-L1blockade", analyzes the acceptance of PD-L1 monoclonal antibody atezolizumab (Art daclizumab, Tecentriq) peripheral blood mononuclear cells and a tumor1445 patients with metastatic urothelial cancer treatment (MUC) and metastatic renal cell cancer patients circulating pIL-8 and IL8 gene expressiona Source: https: //cn.bing.comresearchers found that high levels of plasma, peripheral blood mononuclear cells of IL-8 and tumor Art natalizumab in the transfer and mUC renal cell carcinoma effect in the decreased, even in tumortypical CD8 + T cells in inflammationIn addition, pIL-8 in patients with low baseline levels and to increase mUC Art natalizumab and chemotherapy responseThe researchers also found that patients received treatment mUC in an interview with Art natalizumab therapy without chemotherapy, pIL-8 levels and lower overall survival rate relatedSingle-cell RNA sequencing immune cells display IL8 mainly expressed in myeloid cells and circulating tumor, and IL8 high expression of antigen-presenting downregulation mechanismThus, researchers believe that the treatment of bone marrow capable of reversing inflammation IL-8 mediated immune checkpoint inhibitors to improve vital prognosis of patients with treatmenta (Biovalley Bioon.com) References:Yuen, KC, Liu, L., Gupta, V.etalHighsystemicandtumor-associatedIL-8correlateswithreducedclinicalbenefitofPD-L1blockade .NatMed26, 693-698 (2020) .https: //doi.org/10.1038/s41591-020-0860-1